Study of MK-4464 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced/Metastatic Solid Tumors (MK-4464-001)

Trial Identifier: 4464-001
Sponsor: MSD
Start Date: September 2022
Primary Completion Date: July 2026
Study Completion Date: July 2026
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary- English

Trial Locations

Country Location
Canada, ON Toronto, ON, Canada, M5G 2M9
Israel, N/A Haifa, N/A, Israel, 3109601
Israel, N/A Jerusalem, N/A, Israel, 9112001
Netherlands, Noord-Holland Amsterdam, Noord-Holland, Netherlands, 1081HV
Netherlands, Noord-Holland Amsterdam, Noord-Holland, Netherlands, 1066CX
United States, KY Louisville, KY, United States, 40245